The Svedberg seminar series: Assoc. Prof. Daniel Globisch
September 20 @ 15:15 – 16:30 CEST
SciLifeLab Fellow at Uppsala University / Dept. Chem – BMC
Associate Professor Daniel Globisch started his independent research group as a Science For Life Laboratory Fellow at Uppsala University. In December 2020, Daniel Globisch received tenure and moved with his laboratory to the Department of Chemistry – BMC. He received his PhD in Organic Chemistry and Chemical Biology in 2011 at the Ludwig-Maximilians-University in Munich and joined The Scripps Research Institute, La Jolla, CA for his postdoctoral research in Chemical Biology and Metabolomics from 2011 to 2015. At Uppsala University, his laboratory develops new Chemical Biology methodologies to extend the scope of metabolomics research to discover new biomarkers for pancreatic and colorectal cancer. The interdisciplinary nature of the research projects is focussed on elucidation of the metabolic interaction between the gut microbiota and their human host.
Exploring Gut Microbiota Metabolism – Unique Chemical Biology Tools for Metabolomics Analysis
One of the most exciting scientific developments in the past decade has been the understanding that the microbiome profoundly impacts human physiology. The complex consortium of trillions of microbes possesses a wide range of metabolic activity. This metabolic interspecies communication represents a tremendous opportunity for the discovery of unknown bioactive molecules as only limited information on this co-metabolism has been elucidated on a molecular level. Metabolomics holds a great potential for the discovery of unknown biomarkers and bioactive metabolites. Advanced Chemical Biology tools are limited compared to other ‘omics research fields. Especially, the detailed analysis of microbial metabolism remains a major challenge and requires advanced techniques. We have developed unique Chemical Biology methodologies for enhanced analysis using liquid chromatography-coupled with tandem mass spectrometry. These tools overcome limitations in mass spectrometry-based metabolomics analysis. We apply these methods for the discovery of unknown metabolites in human samples collected from pancreatic cancer patients to evaluate their potential as biomarkers.